A 15.1 months median survival benefit was observed in the EGFR TKI group than in the multimodality therapy group....Patients with advanced lung cancer harbouring EGFR mutations treated with EGFR-TKIs showed better median survival and low risk of mortality than those in the multimodality therapy group.

Of 110 lung SCC patients who received first-generation EGFR-TKI, EGFR-mutated patients had long PFS (p = 0.000) but similar OS (p = 0.472) than patients with EGFR wild type. EGFR-mutated SCC patients who received first-generation EGFR-TKI as a first-line benefit are equal to patients who received first-generation EGFR-TKI as the second line or beyond....Lung SCC patients harboring EGFR mutation received first-generation EGFR-TKI had better clinical survival than patients with EGFR wild type.

The disease control rate(DCR)of the treatment group and control group were 88.6% and 68.6%, respectively, with significant difference(P=0.041)....The 1-year, 2-year, and 3-year overall survival(OS)rates of the treatment group and control group were 62.9% vs 57.1%, 37.1% vs 31.4%, and 8.6% vs 2.9%, respectively. The 1-year, 2-year, and 3-year progression-free survival(PFS)rates of the treatment group and control group were 57.1% vs 31.4%, 20.0% vs 5.7%, and 2.9% vs 0, respectively, with significant differences(P=0.005)....DC-CIK cells combined with EGRF-TKI can improve the disease control rate and patients quality of life, and prolong the PFS in elderly patients with advanced EGFR-mutant lung cancer.